Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24534722 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTTCHRM1 | |
| SCHEMBL29584225 | 0.89 | CHRM2 (0.50) | SMN1; SMN2NPC1RAB9AHTTCHRM1 | |
| SCHEMBL25090677 | 0.89 | CHRM2 (0.50) | SMN1; SMN2NPC1RAB9AHTTCHRM1 | |
| SCHEMBL1207201 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHTTCHRM1 | |
| SCHEMBL27233064 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACHRM1STS | |
| SCHEMBL27233066 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACHRM1STS | |
| SCHEMBL24534725 | 0.85 | CTSL (0.45) | SMN1; SMN2NPC1RAB9AHTTCHRM1 | |
| SCHEMBL24535019 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACHRM1STS | |
| SCHEMBL24535010 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACHRM1STS | |
| SCHEMBL2374261 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AHTTSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999745-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| EP-4263536-A1 | PHARMACEUTICAL COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116848109-A | Pharmaceutical compounds | 赫普泰雅治疗有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20220380379-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-12-01 | — | — | US | disclosed |
| WO-2022129951-A1 | PHARMACEUTICAL COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129951-A1 | PHARMACEUTICAL COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999745-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | SMN1; SMN2 2502/4885NPC1 945/4885RAB9A 1711/4885 |
| US-20220380379-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | SMN1; SMN2 2502/4885NPC1 945/4885RAB9A 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.